Abstract
Atypical antipsychotic-induced hyperprolactinemia can cause important clinical symptoms, particularly in young women and also in men, such as impotence, loss of libido, gynecomastia, anovulation and galactorrhea.
Methods: Observational over one-year follow-up of six patients (four women and two men, mean age of 31.1 years, range 26-37), treated with different atypical antipsychotics in an outpatient psychiatric device, who had clinical complications associated to high prolactin serum levels. All of them were treated with standard doses of cabergoline.
Results: Most patients experienced significant clinical improvement after treatment with standard doses of cabergoline (mean dosage 1.08 mg/week), maintained for a mean of 18 month. Normal prolactin levels were achieved after the first months of treatment with cabergoline. No side effects or worsening of psychotic or behavioral symptoms were observed.
Conclusions: Long-term treatment with cabergoline seems to be safe in atypical antipsychotic-treated patients.
Keywords: Atypical antipsychotics, cabergoline, dopamine, hyperprolactinaemia, hypothalamus, pituitary gland, prolactin, schizophrenia.
Current Drug Safety
Title:Safety of Cabergoline in the Management of Pituitary Prolactin-Induced Symptoms with Patients Treated with Atypical Neuroleptics
Volume: 7 Issue: 2
Author(s): Ramon Coronas, Jesus Cobo, Olga Gimenez-Palop, Emilio Ortega and Manel Marquez
Affiliation:
Keywords: Atypical antipsychotics, cabergoline, dopamine, hyperprolactinaemia, hypothalamus, pituitary gland, prolactin, schizophrenia.
Abstract: Atypical antipsychotic-induced hyperprolactinemia can cause important clinical symptoms, particularly in young women and also in men, such as impotence, loss of libido, gynecomastia, anovulation and galactorrhea.
Methods: Observational over one-year follow-up of six patients (four women and two men, mean age of 31.1 years, range 26-37), treated with different atypical antipsychotics in an outpatient psychiatric device, who had clinical complications associated to high prolactin serum levels. All of them were treated with standard doses of cabergoline.
Results: Most patients experienced significant clinical improvement after treatment with standard doses of cabergoline (mean dosage 1.08 mg/week), maintained for a mean of 18 month. Normal prolactin levels were achieved after the first months of treatment with cabergoline. No side effects or worsening of psychotic or behavioral symptoms were observed.
Conclusions: Long-term treatment with cabergoline seems to be safe in atypical antipsychotic-treated patients.
Export Options
About this article
Cite this article as:
Coronas Ramon, Cobo Jesus, Gimenez-Palop Olga, Ortega Emilio and Marquez Manel, Safety of Cabergoline in the Management of Pituitary Prolactin-Induced Symptoms with Patients Treated with Atypical Neuroleptics, Current Drug Safety 2012; 7 (2) . https://dx.doi.org/10.2174/157488612802715753
DOI https://dx.doi.org/10.2174/157488612802715753 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Benefits of L-Arginine on Cardiovascular System
Mini-Reviews in Medicinal Chemistry Fibroblast Growth Factor 2: From Laboratory Evidence to Clinical Application
Current Vascular Pharmacology Modulation of Individual Susceptibility to the No-Reflow Phenomenon after Acute Myocardial Infarction
Current Pharmaceutical Design Conduction Disorders in the Setting of Acute STEMI
Current Cardiology Reviews Erythropoietin: New Approaches to Improved Molecular Designs and Therapeutic Alternatives
Current Pharmaceutical Design Efficacy and Safety of Antiplatelet Therapies in Symptomatic Peripheral Artery Disease: A Systematic Review and Network Meta-Analysis
Current Vascular Pharmacology Mediterranean Diet and Dementia of the Alzheimer Type
Current Aging Science Cross-talk between Cellular Stress, Cell Cycle and Anticancer Agents: Mechanistic Aspects
Current Medicinal Chemistry - Anti-Cancer Agents The Effect of TNFα-Inhibitors on Cardiovascular Events in Patients with Rheumatoid Arthritis: An Updated Systematic Review of the Literature
Current Rheumatology Reviews HspB5/αB-Crystallin: Properties and Current Progress in Neuropathy
Current Neurovascular Research Vulnerable Plaque and Inflammation: Potential Clinical Strategies
Current Pharmaceutical Design Melatonin and Melatonin Agonists as Adjunctive Treatments in Bipolar Disorders
Current Pharmaceutical Design Innovative Strategy in Treating Angina Pectoris with Chinese Patent Medicines by Promoting Blood Circulation and Removing Blood Stasis: Experience from Combination Therapy in Chinese Medicine
Current Vascular Pharmacology The Metabolic Treatment of Patients with Coronary Artery Disease: Effects on Quality of Life and Effort Angina
Current Pharmaceutical Design Circadian MicroRNAs in Cardioprotection
Current Pharmaceutical Design The No-Reflow Phenomenon in the Coronary Circulation
Cardiovascular & Hematological Agents in Medicinal Chemistry Atrial Fibrillation in Acute St-Elevation Myocardial Infarction: Clinical and Prognostic Features
Current Cardiology Reviews Potentiating the Naturally Occurring Process for Repair of Damaged Heart
Current Pharmaceutical Design Fractional Flow Reserve: Physiological Basis, Advantages and Limitations, and Potential Gender Differences
Current Cardiology Reviews Therapeutic Angiogenesis for Islet Revascularization
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)